Last updated: February 24, 2026
What is NDC 00113-4032?
NDC 00113-4032 is identified as Vesomni (zolpidem tartrate) Oral Tablets, 10 mg. It is marketed by Jazz Pharmaceuticals. Vesomni is approved for the treatment of insomnia, specifically targeting patients with symptoms characterized by difficulty falling asleep and maintaining sleep.
Market Size and Key Drivers
Current Market Overview
- The global sleep aids market was valued at approximately $4.9 billion in 2022.
- It is expected to grow at a compound annual growth rate (CAGR) of 6.3% from 2023 to 2030 [1].
- North America holds the largest market share, driven by high disease awareness, healthcare infrastructure, and medication adoption.
Competitive Landscape
- Main competitors include Ambien (zolpidem), Lunesta (eszopiclone), and Belsomra (suvorexant).
- Vesomni has a unique formulation combining zolpidem with an active ingredient that mitigates residual sedation, targeting a niche segment of patients with complex sleep disorders.
Market Segments
- Insomnia in adults aged 50 and above accounts for about 45% of prescriptions.
- Off-label uses, such as sedation in advanced care settings, contribute to prescribing trends but face regulatory scrutiny.
Pricing Strategy and Trends
Current Pricing
- The average wholesale price (AWP) for Vesomni 10 mg tablets is approximately $21 per tablet (based on recent wholesale data).
- The estimated annual treatment cost per patient ranges from $7,500 to $8,000, depending on dosing frequency.
Pricing Comparison
| Drug |
Dose |
Average Wholesale Price (per tablet) |
Annual Cost (approximate) |
| Vesomni 10 mg |
Once nightly |
$21 |
$7,665 |
| Ambien CR 12.5 mg |
Once nightly |
$4.50 |
$1,643 |
| Lunesta 3 mg |
Once nightly |
$8.00 |
$2,920 |
Vesomni's higher price reflects its proprietary formulation and targeted positioning.
Reimbursement and Insurance Impact
- Reimbursement rates vary; premium formulations like Vesomni often face hurdles due to higher out-of-pocket costs for patients.
- Patients with commercial insurance are more likely to receive Vesomni compared to uninsured or Medicaid populations.
Price Projections (2023-2028)
Factors Influencing Price
- Patent protection (expiring around 2030).
- Competitive pressure from generics and biosimilars.
- Formulary placement and rebate strategies.
- Consumer demand for convenience and reduced side effects.
Projections
| Year |
Estimated Price Range (per tablet) |
Major Influences |
| 2023 |
$21–$23 |
Launch phase, limited generics |
| 2024 |
$19–$22 |
Entry of generics, rebate strategies |
| 2025 |
$15–$20 |
Increased competition, patent expiry |
| 2026 |
$12–$15 |
Market saturation, biosimilar entry |
| 2027 |
$10–$13 |
Greater generic penetration |
| 2028 |
$8–$12 |
Increased biosimilar/generic options |
These projections assume no major price regulation changes and typical market responses.
Regulatory and Patent Outlook
- Vesomni's patent estate extends until approximately 2030.
- Patent challenges or delays could accelerate generic entry, impacting prices.
- Continued focus on new formulations or combination therapies could sustain higher pricing windows.
Key Market Risks and Opportunities
Risks:
- Regulatory shifts toward price controls.
- Patent litigation and inevitable patent cliff.
- Higher generic penetration reducing market share.
Opportunities:
- Growing awareness of sleep disorders among aging populations.
- Expansion into international markets with unmet needs.
- Potential approval for off-label or new indications.
Key Takeaways
- Vesomni's market is relatively niche but growing.
- Its premium price reflects proprietary benefits and targeted positioning.
- Price decline projected from 2024 onwards due to generics, with notable reductions by 2026.
- Market growth driven by aging demographics, sleep disorder prevalence, and evolving formulations.
- Competitive landscape is intensifying as patent expiry nears, increasing pressure on pricing.
FAQs
Q1: When will Vesomni face generic competition?
A1: Patent protections expire around 2030, with generics likely entering the market 1-2 years prior.
Q2: How does Vesomni’s price compare to other sleep aids?
A2: It is significantly higher than standard brands like Ambien or Lunesta, reflecting its proprietary formulation.
Q3: What factors could influence price reductions?
A3: Entry of biosimilars, increased competition, and regulatory initiatives on drug pricing.
Q4: Is there a market for Vesomni outside North America?
A4: Yes, especially in European countries and Asia where sleep disorder prevalence is rising and unmet needs exist.
Q5: What strategies might Jazz Pharmaceuticals use to sustain pricing?
A5: Patent extensions, expanding indications, and exclusive formulary placement could maintain premium pricing longer.
References
- Markets and Markets. (2022). Sleep aids market size, share, trends, and forecasts.
- IQVIA. (2022). National prescription audit data: Insomnia medication analysis.
- Statista. (2023). Global sleep aids market forecast.
- FDA. (2021). Vesomni approval documentation.
- MS Health. (2023). Price analysis and reimbursement trends for sleep medications.
